Tumor microenvironment complexity: emerging roles in cancer therapy.

The tumor microenvironment (TME) consists of cells, soluble factors, signaling molecules, extracellular matrix, and mechanical cues that can promote neoplastic transformation, support tumor growth and invasion, protect the tumor from host immunity, foster therapeutic resistance, and provide niches for dormant metastases to thrive. An American Association for Cancer Research (AACR) special conference held on November 3-6, 2011, addressed five emerging concepts in our understanding of the TME: its dynamic evolution, how it is educated by tumor cells, pathways of communication between stromal and tumor cells, immunomodulatory roles of the lymphatic system, and contribution of the intestinal microbiota. These discussions raised critical questions on how to include the analysis of the TME in personalized cancer diagnosis and treatment.

[1]  Mark T. W. Ebbert,et al.  Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes , 2011, Nature Medicine.

[2]  M. Bertagnolli,et al.  Mesenchymal stromal cell mutations and wound healing contribute to the etiology of desmoid tumors. , 2012, Cancer research.

[3]  W. Dougall.  Molecular Pathways: Osteoclast-Dependent and Osteoclast-Independent Roles of the RANKL/RANK/OPG Pathway in Tumorigenesis and Metastasis , 2011, Clinical Cancer Research.

[4]  Naveena Singh,et al.  Interleukin-6 as a Therapeutic Target in Human Ovarian Cancer , 2011, Clinical Cancer Research.

[5]  Michael C. Ostrowski,et al.  NF-kappaB activation within macrophages leads to an anti-tumor phenotype in a mammary tumor lung metastasis model , 2011, Breast Cancer Research.

[6]  Karin Jirström,et al.  Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. , 2011, Cancer discovery.

[7]  Melody A. Swartz,et al.  Induction of Lymphoidlike Stroma and Immune Escape by Tumors That Express the Chemokine CCL21 , 2010, Science.

[8]  B. Fingleton,et al.  Matrix Metalloproteinase Inhibitors and Cancer—Trials and Tribulations , 2002, Science.

[9]  D. Steinhilber,et al.  Lipoxygenase mediates invasion of intrametastatic lymphatic vessels and propagates lymph node metastasis of human mammary carcinoma xenografts in mouse. , 2011, The Journal of clinical investigation.

[10]  Michael Karin,et al.  Inflammation meets cancer, with NF-κB as the matchmaker , 2011, Nature Immunology.

[11]  T. Sacktor.  How does PKMζ maintain long-term memory? , 2011, Nature Reviews Neuroscience.

[12]  G. Rabinovich,et al.  Neuroblastoma triggers an immunoevasive program involving galectin‐1‐dependent modulation of T cell and dendritic cell compartments , 2012, International journal of cancer.

[13]  Robert A. Gatenby,et al.  Environment-mediated drug resistance: a major contributor to minimal residual disease , 2009, Nature Reviews Cancer.

[14]  S. Hewitt,et al.  Podoplanin expression in cancerous stroma induces lymphangiogenesis and predicts lymphatic spread and patient survival. , 2010, Archives of pathology & laboratory medicine.

[15]  M. Swartz,et al.  Role of Lymphatic Vessels in Tumor Immunity: Passive Conduits or Active Participants? , 2010, Journal of Mammary Gland Biology and Neoplasia.

[16]  D. Ribatti.  From the discovery of Vascular Endothelial Growth Factor to the introduction of Avastin in clinical trials - an interview with Napoleone Ferrara , 2011 .

[17]  M. Detmar,et al.  Interaction of tumor cells and lymphatic vessels in cancer progression , 2012, Oncogene.

[18]  Erik Sahai,et al.  ROCK and JAK1 signaling cooperate to control actomyosin contractility in tumor cells and stroma. , 2011, Cancer cell.

[19]  George Coukos,et al.  Cancer immunotherapy comes of age , 2011, Nature.

[20]  Matthew J. Paszek,et al.  Balancing forces: architectural control of mechanotransduction , 2011, Nature Reviews Molecular Cell Biology.

[21]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[22]  M. Colombo,et al.  SPARC oppositely regulates inflammation and fibrosis in bleomycin-induced lung damage. , 2011, The American journal of pathology.

[23]  R. DuBois,et al.  COX-2 inhibition and colorectal cancer. , 2004, Seminars in oncology.

[24]  H. Dvorak,et al.  Tumor microenvironment and progression , 2011, Journal of surgical oncology.

[25]  A. Witteveen,et al.  Converting a breast cancer microarray signature into a high-throughput diagnostic test , 2006, BMC Genomics.

[26]  L. Coussens,et al.  B regulatory cells and the tumor-promoting actions of TNF-α during squamous carcinogenesis , 2011, Proceedings of the National Academy of Sciences.

[27]  N. Bertos,et al.  Breast cancer - one term, many entities? , 2011, The Journal of clinical investigation.

[28]  M. Detmar,et al.  Watching lymphatic vessels grow by making them glow , 2011, Cell Research.

[29]  G. Friedman,et al.  Helicobacter pylori infection and the risk of gastric carcinoma. , 1991, The New England journal of medicine.

[30]  Brian Keith,et al.  HIF1α and HIF2α: sibling rivalry in hypoxic tumour growth and progression , 2011, Nature Reviews Cancer.

[31]  W. Dougall.  Osteoclast-dependent and-independent roles of the RANKL/RANK/OPG pathway in tumorigenesis and metastasis , 2011 .

[32]  N. Ferrara.  From the discovery of vascular endothelial growth factor to the introduction of avastin in clinical trials - an interview with Napoleone Ferrara by Domenico Ribatti. , 2011, The International journal of developmental biology.

[33]  M. Wong,et al.  Fusion between Intestinal epithelial cells and macrophages in a cancer context results in nuclear reprogramming. , 2011, Cancer research.

[34]  E. Sahai,et al.  Cell communication networks in cancer invasion. , 2011, Current opinion in cell biology.

[35]  D. Lyden,et al.  The secreted factors responsible for pre-metastatic niche formation: old sayings and new thoughts. , 2011, Seminars in cancer biology.

[36]  G. Shurin,et al.  Regulatory dendritic cells in the tumor immunoenvironment , 2012, Cancer Immunology, Immunotherapy.

[37]  A. Ruddell,et al.  B lymphocytes promote lymphogenous metastasis of lymphoma and melanoma. , 2011, Neoplasia.

[38]  J. Fox,et al.  Helicobacter hepaticus infection in mice: models for understanding lower bowel inflammation and cancer , 2010, Mucosal Immunology.

[39]  Laurence Zitvogel,et al.  Exosomes: composition, biogenesis and function , 2002, Nature Reviews Immunology.

[40]  Kenneth J Pienta,et al.  Mechanisms of cancer cell metastasis to the bone: a multistep process. , 2011, Future oncology.